Company / SG&A Expense
Taysha Gene Therapies, Inc. SG&A Expense History
FY2020-FY2025 · Annual data · Source: SEC filings
At a glance
Latest annual filing availableLatest SG&A Expense
$33.9M
FY2025
5-year range
$30.0M / $41.3M
FY2021-FY2025
Trend
+12.7%
vs FY2024
Sector context
#180 of 213
Health Care
What the data says
Taysha Gene Therapies, Inc.'s sg&a expense of $34M is lower than 85% of companies in the Health Care sector (FY2025). SG&A Expense returned to growth in FY2025 after 2 years of decline, reaching $34M.
Based on SEC 10-K filings.
$34M in FY2025 with a 5-year CAGR of +25.0%.
Improved from $37M to $34M over the past 2 years.
Health Care sector context is included.
SG&A Expense over time
Growth rates
- 3-Year CAGR
- -6.4%
- 5-Year CAGR
- +25.0%
- 10-Year CAGR
- -
Sector benchmark
Top 15% in Health CareTop 15% of 213This company $33.9M Sector average $722.3M
▼
-95.3% below sector average
Key checks
Key Insights
- 5-year CAGR of +25.0%, indicating consistent growth.
- In FY2025, sg&a expense increased 12.7% year-over-year.
- Ranks #180 out of 213 companies in the Health Care sector.
- Peak sg&a expense was recorded in FY2022.
Company context
Key Data Points
- Altman Z-Score -1.03 (distress zone, below 1.8 threshold)
- High earnings quality (cash-backed earnings)
Data sourced from SEC EDGAR filings. Not investment advice.
Annual data
| Year | SG&A ExpenseValue | YoY GrowthYoY |
|---|---|---|
| FY2025 | $33.9M | +12.7% |
| FY2024 | $30.0M | -19.6% |
| FY2023 | $37.4M | -9.6% |
| FY2022 | $41.3M | +0.0% |
| FY2021 | $41.3M | +272.0% |
| FY2020 | $11.1M | - |
As of FY2025 · SEC 10-K · Updated Jun 30, 2026